3-isopropyl-1-thia-3-azacyclohexane | 60035-86-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: 3-isopropyl-1-thia-3-azacyclohexane
• 英文别名: 3-Isopropyl-tetrahydro-1,3-thiazin；3-isopropyl-[1,3]thiazinane；InChI=1/C7H15NS/c1-7(2)8-4-3-5-9-6-8/h7H,3-6H2,1-2H；3-propan-2-yl-1,3-thiazinane
• CAS: 60035-86-1
• 化学式: C₇H₁₅NS
• 分子量: 145.269
• InChiKey: UQLSFYIQEIQMEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  28.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3-bromo-N-isopropylpropan-1-amine hydrobromide 以 水 为溶剂， 生成 3-isopropyl-1-thia-3-azacyclohexane
  参考文献：
  名称：

  Angiolini,L. et al., Gazzetta Chimica Italiana, 1976, vol. 106, p. 111 - 118

  摘要：

  DOI：

文献信息

• AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
  申请人：Allen Jennifer R.

  公开号：US20100160280A1

  公开（公告）日：2010-06-24

  Pyridine and pyrimidine compounds: or a pharmaceutically acceptable salt thereof, wherein m, n, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , and Y are as defined in the specification; or a pharmaceutically acceptable salt thereof, wherein ring A, m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; and or a pharmaceutically acceptable salt thereof, wherein m, n, y, R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 9 , X 1 , X 2 , and ring A are as defined in the specification; compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

  吡啶和嘧啶化合物： 或者是根据说明书中定义的药用可接受盐，其中m、n、R1、R2、R3、R4、R5、R6、R7、X1、X2、X3、X4、X5、X6、X7、X8和Y都有所定义； 或者是根据说明书中定义的药用可接受盐，其中环A、m、n、y、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和环A都有所定义； 或者是根据说明书中定义的药用可接受盐，其中m、n、y、R2、R3、R4、R5、R6、R7、R9、X1、X2和环A都有所定义；含有它们的组合物以及制备这类化合物的方法。还提供了通过抑制PDE10治疗可治疗的疾病或病症的方法，例如肥胖、非胰岛素依赖型糖尿病、精神分裂症、双相情感障碍、强迫症等。
• MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR
  申请人：Miller Mark Thomas

  公开号：US20170196862A2

  公开（公告）日：2017-07-13

  The present invention features a compound of formula I: or a pharmaceutically acceptable salt thereof, where R 1 , R 2 , R 3 , W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.
• PHENYLSULFONYLUREA DERIVATIVES USEFUL AS NLRP3 INHIBITORS
  申请人：Inflazome Limited

  公开号：US20210332020A1

  公开（公告）日：2021-10-28

  The present invention relates to phenylsulfonylureas and phenylsulfonylthioureas, wherein the phenyl ring is substituted with a monovalent group comprising either (i) an aryl or a heteroaryl group, or (ii) a nitrogen-containing heterocyclic group, and wherein the group attached to the terminal nitrogen atom of the urea group is a 6-membered cyclic group substituted at the 2- and 4-positions. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by NLRP 3 inhibition.
• US8637500B2
  申请人：——

  公开号：US8637500B2

  公开（公告）日：2014-01-28
• Angiolini,L. et al., Gazzetta Chimica Italiana, 1976, vol. 106, p. 111 - 118
  作者：Angiolini,L. et al.

  DOI：——

  日期：——

表征谱图